# Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma

> **NCT02590263** · PHASE1,PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 53 (actual)

## Conditions studied

- Malignant Glioma
- Glioblastoma Multiforme

## Interventions

- **RADIATION:** Whole Brain Radiation
- **DRUG:** Temozolomide
- **DRUG:** ABT-414

## Key facts

- **NCT ID:** NCT02590263
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-24
- **Primary completion:** 2020-08-27
- **Final completion:** 2020-08-27
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2020-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02590263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02590263, "Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02590263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*